NewCo News: Living Up to its Acronym, ACT Nears Telatinib Phase III
By Tom Wall
Friday, May 13, 2011
The "ACT" in ACT Biotech Inc. stands for "accelerate cancer therapeutics" and the 3-year-old San Francisco-based company is living up to its acronym as it nears the start of a Phase III trial in the second half of this year of lead candidate telatinib in combination with chemotherapy for the first-line treatment of advanced stomach cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.